The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Significance of immunohistochemistry in breast cancer
Open accessAbstract
The biological characteristics of the tumour are used to estimate prognosis and select appropriate systemic therapy for patients with (breast) cancer. The advent of molecular technology has incorporated new biomarkers along with immunohistochemical and serum biomarkers. Immunohistochemical markers are often used to guide treatment decisions, to classify breast cancer into subtypes that are biologically distinct and behave differently, and both as prognostic and predictive factors. Steroid hormone receptors, markers of tumour proliferation, and factors involved in angiogenesis and apoptosis are of scientific interest. In this review we will provide information on the immunohistochemical markers used in the management of breast cancer patients using available data from the literature. We consider the utility of established immunohistochemical markers, and discuss the challenges involved in integrating novel molecular markers into clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2775 · Cited by 4,434
Harris, L., Fritsche, H., Mennel, R., Norton, L., Ravdin, P., Taube, S., Somerfield, M. R., Hayes, D. F., & Bast, R. C. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.2364 · Cited by 2,217
Prognostic and predictive factors in breast cancer by immunohistochemical analysis.
Allred, D. C., Harvey, J. M., Berardo, M. D., & Gm, C. (1998) · PubMed · Cited by 2,143
Tsujimoto, Y., Finger, L. R., Yunis, J., Nowell, P. C., & Croce, C. M. (1984) · Science · doi:10.1126/science.6093263 · Cited by 1,769
Wolff, A. C., Hammond, M. E. H., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., Allred, D. C., Bartlett, J. M. S., Bilous, M., Fitzgibbons, P., et al. (2014) · Archives of Pathology and Laboratory Medicine · doi:10.5858/arpa.2013-0953-sa · Cited by 1,762
p53 Status and the Efficacy of Cancer Therapy in Vivo
Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E., & Jacks, T. (1994) · Science · doi:10.1126/science.7973635 · Cited by 1,469
Ki67 in breast cancer: prognostic and predictive potential
Yerushalmi, R., Woods, R., Ravdin, P. M., Hayes, M. M., & Gelmon, K. A. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70262-1 · Cited by 1,207
Goldhirsch, A., Glick, J. H., Gelber, R. D., Coates, A. S., Thürlimann, B., & Senn, H.-J. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi326 · Cited by 1,127
Fisher, B., Dignam, J., Wolmark, N., Wickerham, D. L., Fisher, E. R., Mamounas, E., Smith, R., Begovic, M., Dimitrov, N. V., Margolese, R. G., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)05036-9 · Cited by 1,040
TP53 mutations in human cancers: Functional selection and impact on cancer prognosis and outcomes
Petitjean, A., Achatz, M. I. W., Borresen-Dale, A. L., Hainaut, P., & Olivier, M. (2007) · Oncogene · doi:10.1038/sj.onc.1210302 · Cited by 884
Horak, E. R., Klenk, N., Leek, R., LeJeune, S., Smith, K., Stuart, N., Harris, A. L., Greenall, M., & Stepniewska, K. (1992) · The Lancet · doi:10.1016/0140-6736(92)93150-l · Cited by 800
Dowsett, M., Smith, I. E., Ebbs, S. R., Dixon, J. M., Skene, A., A'Hern, R., Salter, J., Detre, S., Hills, M., & Walsh, G. (2007) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djk020 · Cited by 665
Ellis, M. J., Tao, Y., Luo, J., A'Hern, R., Evans, D. B., Bhatnagar, A. S., Chaudri Ross, H. A., von Kameke, A., Miller, W. R., Smith, I., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn309 · Cited by 653
Schneider, B. P., Wang, M., Radovich, M., Sledge, G. W., Badve, S., Thor, A., Flockhart, D. A., Hancock, B., Davidson, N., Gralow, J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.1612 · Cited by 604
Inwald, E. C., Klinkhammer-Schalke, M., Hofstädter, F., Zeman, F., Koller, M., Gerstenhauer, M., & Ortmann, O. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2560-8 · Cited by 601
Paik, S., Hazan, R., Fisher, E. R., Sass, R. E., Fisher, B., Redmond, C., Schlessinger, J., Lippman, M. E., & King, C. R. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.1.103 · Cited by 594
FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?
Fischer, C., Mazzone, M., Jonckx, B., & Carmeliet, P. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2524 · Cited by 568
FISHER, B. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90133-2 · Cited by 516
Silvestrini, R., Veneroni, S., Daidone, M. G., Benini, E., Boracchi, P., Mezzetti, M., di Fronzo, G., Rilke, F. O., & Veronesi, U. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.7.499 · Cited by 454
p63, a p53 Homologue, Is a Selective Nuclear Marker of Myoepithelial Cells of the Human Breast
Barbareschi, M., Pecciarini, L., Cangi, M. G., Macrì, E., Rizzo, A., Viale, G., & Doglioni, C. (2001) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200108000-00010 · Cited by 384
The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry.
O'Reilly, L. A., Huang, D. C., & Strasser, A. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb01090.x · Cited by 377
Adams, J., Carder, P. J., Downey, S. E., Forbes, M. A., MacLennan, K. A., Allgar, V. L., Kaufman, S., Hallam, S., Bicknell, R., Walker, J. J., et al. (2000) · PubMed · Cited by 339
Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment
Fasching, P. A., Heusinger, K., Haeberle, L., Niklos, M., Hein, A., Bayer, C. M., Rauh, C., Schulz-Wendtland, R., Bani, M. R., Schrauder, M., et al. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-486 · Cited by 328
Dawson, S.-J., Makretsov, N., Blows, F. M., Driver, K. E., Provenzano, E., Le Quesne, J., Baglietto, L., Severi, G., Giles, G. G., McLean, C. A., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605736 · Cited by 317
Acs, G., Lawton, T. J., Rebbeck, T. R., LiVolsi, V. A., & Zhang, P. J. (2001) · American Journal of Clinical Pathology · doi:10.1309/fdhx-l92r-batq-2ge0 · Cited by 280
Barnes, D., Harris, W., Smith, P., Millis, R., & Rubens, R. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.563 · Cited by 241
Bcl-2 Is a Prognostic Marker in Breast Cancer Independently of the Nottingham Prognostic Index
Callagy, G. M., Pharoah, P. D., Pinder, S. E., Hsu, F. D., Nielsen, T. O., Ragaz, J., Ellis, I. O., Huntsman, D., & Caldas, C. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2719 · Cited by 237
Keam, B., Im, S.-A., Lee, K.-H., Han, S.-W., Oh, D.-Y., Kim, J. H., Lee, S.-H., Han, W., Kim, D.-W., Kim, T.-Y., et al. (2011) · Breast Cancer Research · doi:10.1186/bcr2834 · Cited by 235
Decensi, A., Robertson, C., Viale, G., Pigatto, F., Johansson, H., Kisanga, E. R., Veronesi, P., Torrisi, R., Cazzaniga, M., Mora, S., et al. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.11.779 · Cited by 221
HER2 Testing in Breast Cancer: NCCN Task Force Report and Recommendations
Carlson, R. W., Moench, S. J., Hammond, M. E. H., Perez, E. A., Burstein, H. J., Allred, D. C., Vogel, C. L., Goldstein, L. J., Somlo, G., Gradishar, W. J., et al. (2006) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2006.2003 · Cited by 205
Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer
Callagy, G. M., Webber, M. J., Pharoah, P. D., & Caldas, C. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-153 · Cited by 193
Ghosh, S., Sullivan, C. A. W., Zerkowski, M. P., Molinaro, A. M., Rimm, D. L., Camp, R. L., & Chung, G. G. (2008) · Human Pathology · doi:10.1016/j.humpath.2008.06.004 · Cited by 182
St. Gallen 2013: Brief Preliminary Summary of the Consensus Discussion
Harbeck, N., Thomssen, C., & Gnant, M. (2013) · Breast Care · doi:10.1159/000351193 · Cited by 174
Dai, M.-S., Sun, X.-X., & Lu, H. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01662-07 · Cited by 172
Lipponen, P., Pietiläinen, T., Kosma, V., Aaltomaa, S. H., Eskelinen, M., & Syrjäunen, K. (1995) · The Journal of Pathology · doi:10.1002/path.1711770109 · Cited by 156
A Robust Automated Measure of Average Antibody Staining in Immunohistochemistry Images
Choudhury, K. R., Yagle, K. J., Swanson, P. E., Krohn, K. A., & Rajendran, J. G. (2009) · Journal of Histochemistry & Cytochemistry · doi:10.1369/jhc.2009.953554 · Cited by 152
Jarasch, E.-D., Nagle, R. B., Kaufmann, M., Maurer, C., & Böcker, W. (1988) · Human Pathology · doi:10.1016/s0046-8177(88)80520-3 · Cited by 131
Is the Ki-67 labelling index ready for clinical use?
Jonat, W., & Arnold, N. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq732 · Cited by 125
Li, X., Lee, C., Tang, Z., Zhang, F., Arjunan, P., Li, Y., Hou, X., Kumar, A., & Dong, L. (2009) · Cell Adhesion & Migration · doi:10.4161/cam.3.4.9459 · Cited by 119
Lehr, H., Folpe, A. L., Yaziji, H., Kommoss, F., & Gown, A. M. (2000) · American Journal of Clinical Pathology · doi:10.1309/cpux-kweh-7b26-ye19 · Cited by 119
Mammaglobin, a Breast‐Specific Gene, and Its Utility as a Marker for Breast Cancer
Fleming, T. P., & Watson, M. A. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb05521.x · Cited by 110
First—select the target: better choice of adjuvant treatments for breast cancer patients
Goldhirsch, A., Coates, A. S., Gelber, R. D., Glick, J. H., Thurlimann, B. J. K., & Senn, H.-J. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl398 · Cited by 97
The impact of p53 in predicting clinical outcome of breast cancer patients with visceral metastasis
Yang, P., Du, C., Kwan, M., Liang, S.-X., & Zhang, G. J. (2013) · Scientific Reports · doi:10.1038/srep02246 · Cited by 94
Fisher, E. R., Anderson, S., Dean, S., Dabbs, D. J., Fisher, B., Siderits, R. H., Pritchard, J., Pereira, T. C., Geyer, C. E., & Wolmark, N. (2004) · Cancer · doi:10.1002/cncr.20761 · Cited by 93
Immunohistochemical localization of actin
Mukai, K., Schollmeyer, J. V., & Rosaí, J. (1981) · The American Journal of Surgical Pathology · doi:10.1097/00000478-198101000-00013 · Cited by 93
Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer
Linjawi, A., Kontogiannea, M., Halwani, F., Edwardes, M., & Meterissian, S. H. (2003) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2003.08.008 · Cited by 91
Yamashita, H., Toyama, T., Nishio, M., Ando, Y., Hamaguchi, M., Zhang, Z., Kobayashi, S., Fujii, Y., & Iwase, H. (2006) · Breast Cancer Research · doi:10.1186/bcr1536 · Cited by 87
Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients
Alsner, J., Yilmaz, M. K., Guldberg, P., Hansen, L. L., & Overgaard, J. (2000) · Breast Cancer Research · doi:10.1186/bcr109 · Cited by 79
Immunologic Proliferation Marker Ki-S2 as Prognostic Indicator for Lymph Node-Negative Breast Cancer
Rudolph, P., Alm, P., Heidebrecht, H. J., Bolte, H., Ratjen, V., Baldetorp, B., Fernö, M., Olsson, H. L., & Parwaresch, R. M. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.3.271 · Cited by 73
Rykałą, J., Przybyłowska, K., Majsterek, I., Pasz‐Walczak, G., Sygut, A., Dziki, A. J., & Kruk‐Jeromin, J. (2011) · Pathology & Oncology Research · doi:10.1007/s12253-011-9387-6 · Cited by 71
Identification of Mammaglobin as a Novel Serum Marker for Breast Cancer
Bernstein, J. L., Godbold, J., Raptis, G., Watson, M. A., Levinson, B., Aaronson, S. A., & Fleming, T. P. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0415 · Cited by 70
Reappraising antiangiogenic therapy for breast cancer
Kerbel, R. S. (2011) · The Breast · doi:10.1016/s0960-9776(11)70295-8 · Cited by 69
Estimation of Immunohistochemical Expression of VEGF in Ductal Carcinomas of the Breast
Maae, E., Nielsen, M., Steffensen, K. D., Jakobsen, E. H., Jakobsen, A. K. M., & Sørensen, F. B. (2011) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155411412599 · Cited by 51
Charpin, C., Garcia, S., Bonnier, P., Martini, F., Andrac, L., Horschowski, N., Lavaut, M., & Allasia, C. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.6.2025 · Cited by 51
p53 as a Marker of Prognosis in African-American Women with Breast Cancer
Dookeran, K. A., Dignam, J. J., Ferrer, K., et al. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0889-3 · Cited by 50
Tsubura, A., Shikata, N., Inui, T., et al. (1988) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/bf00749674 · Cited by 48
Rudolph, P., Alm, P., Olsson, H. L., Heidebrecht, H.-J., Fernö, M., Baldetorp, B., & Parwaresch, R. M. (2001) · Human Pathology · doi:10.1053/hupa.2001.22748 · Cited by 41
Cited by
Digital pathology and artificial intelligence
Niazi, M. K. K., Parwani, A. V., & Gurcan, M. N. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30154-8 · Cited by 1,232
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
Zhang, J., Mu, N., Liu, L., Xie, J., Feng, H., Yao, J., Chen, T., & Zhu, W. (2021) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2021.113241 · Cited by 325
Comprehensive omic characterization of breast cancer in Mexican-Hispanic women
Romero-Cordoba, S. L., Salido-Guadarrama, I., Rebollar-Vega, R., Bautista-Piña, V., Dominguez-Reyes, C., Tenorio-Torres, A., Villegas-Carlos, F., Fernández-López, J. C., Uribe-Figueroa, L., Alfaro-Ruiz, L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22478-5 · Cited by 291
Metadata
- Authors
- Zaha, D. C.
- Venue
- World Journal of Clinical Oncology
- Publisher
- Baishideng Publishing Group Inc.
- Published
- 2014
- Volume
- 5
- Issue
- 3
- Pages
- 382
- ISSN
- 2218-4333 (ISSN-L)
- OpenAlex
- W2049420719
- Cited by
- 277
- References
- 58
- FWCI
- 2.24
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.